STOCK TITAN

Dare Bioscience, Inc. - $DARE STOCK NEWS

Welcome to our dedicated page for Dare Bioscience news (Ticker: $DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dare Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dare Bioscience's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Dare Bioscience, Inc.

Nasdaq:DARE

DARE Rankings

DARE Stock Data

31.30M
98.89M
1.65%
6.63%
0.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About DARE

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.